OptraSCAN receives USFDA 510(k) clearance for its integrated digital pathology system supporting HER2 assessment and clinical pathology workflows.
Read MoreBreast cancer
Bioneemtec to Commercialize Advanced API and Liposomal Technologies with TDB-DST Support
Bioneemtec receives TDB-DST support to commercialize green chemistry-based pharmaceutical manufacturing technologies, APIs and advanced drug liposomes.
Read More
Alkem launches Pertuza biosimilar in India for HER2-positive breast cancer treatment
Alkem launches Pertuza biosimilar in India, offering affordable HER2-positive breast cancer treatment and strengthening its oncology portfolio.
Read More